{
    "clinical_study": {
        "@rank": "77212", 
        "arm_group": {
            "arm_group_label": "NovoSeven\u00ae (activated recombinant factor VII)"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy\n      of NovoSeven\u00ae (activated recombinant factor VII, eptacog alfa (activated)) during bleeding\n      episodes and for the prevention of bleeding during surgery/delivery in patients with\n      Glanzmann's thrombasthenia (GT)/Glanzmann's disease."
        }, 
        "brief_title": "A Study to Evaluate Safety and Efficacy of NovoSeven\u00ae in Patients With Glanzmann's Thrombasthenia in Japan", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Glanzmann's Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemorrhage", 
                "Thrombasthenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any study-related activities (Study related activity\n             are any procedure related to recording of data according to the protocol).\n\n          -  All-treated patients in the registration period\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy to study product(s) or related products\n\n          -  Septicaemia (especially, septicaemia followed severely infected patients caused by\n             gram-negative bacteria [The risk of DIC (disseminated intravascular coagulation)\n             caused by endotoxemia could not denied]\n\n          -  Patients with a history of hypersensitivity to any of the product components"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients with GT, who are enrolled in this study and to whom activated recombinant\n        human factor VII (NovoSeven\u00ae) is administered in the study period, shall be included."
            }
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876745", 
            "org_study_id": "F7HAEM-4030", 
            "secondary_id": "U1111-1139-9589"
        }, 
        "intervention": {
            "arm_group_label": "NovoSeven\u00ae (activated recombinant factor VII)", 
            "description": "Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.", 
            "intervention_name": "eptacog alfa (activated)", 
            "intervention_type": "Drug", 
            "other_name": [
                "activated recombinant factor VII", 
                "NovoSeven\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 13, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "1000005"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven\u00ae in Patients With Glanzmann's Thrombasthenia in Japan", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Therapy-related thrombosis", 
            "safety_issue": "No", 
            "time_frame": "From onset of treatment until 6 hours after treatment onset"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876745"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall efficacy evaluated by the caregiver/patient: effective, partially effective, ineffective or not possible to evaluate", 
                "safety_issue": "No", 
                "time_frame": "Within 30 days of end of treatment for bleeding episodes"
            }, 
            {
                "measure": "Overall efficacy evaluated by the caregiver/patient: effective, partially effective, ineffective or not possible to evaluate", 
                "safety_issue": "No", 
                "time_frame": "Within 24 hours after surgery for surgery/delivery"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}